Sandra Aung, Ph.D.

Dr. Sandra Aung is responsible for overseeing the clinical development of the Ambrx pipeline. Dr. Aung brings over 20 years of experience in the pharmaceutical and biotechnology industry to her new role. Prior to Ambrx, Dr. Aung was Chief Clinical Development Officer at Oncosec Medical. Dr. Aung was previously with Nektar Therapeutics’ supporting the development of pegylated interleukin-2, and earlier in her career she held research and leadership positions at UbiVac, Inc. and Cell Genesys. Dr. Aung brings cross industry and academic relationships with Key Opinion Leaders (KOLs) and extensive drug development experience. Dr. Aung has a versatile background in autoimmunity, immune-oncology, and infectious disease and has authored over 30 peer-reviewed publications and received multiple Small Business Innovate Research (SBIR) grants from the National Cancer Institute/ National Institutes of Health.

Dr. Aung earned her Ph.D. in microbiology and immunology from Vanderbilt University and performed her post-doctoral research at The Scripps Research Institute.